Both options have minimal interaction risk with semaglutide and can be used regularly without building tolerance
After week 48, with the start of the open-label treatment extension period, group 1 (placebo) and group 2 (bimagrumab 10 mg kg 1 ) switched to receive bimagrumab 30 mg kg 1 every 12 weeks without the loading dose
Conversely, weight loss medications like Zepbound and Wegovy are frequently covered if weight-related health conditions justify their use, often requiring prior authorization
Some patients believe that extending the interval between injections may reduce the severity of these side effects
Retatrutide , a triple agonist targeting GLP-1, GIP, and glucagon receptors, represents the next generation, and the retatrutide calculator supports dosing for those exploring that compound
"WHO advisers to consider whether obesity medication should be added to Essential Medicines List"